Pass Your RAPS Exam with RAC-US Exam Dumps (Updated 100 Questions)
RAC-US Exam Dumps - RAPS Practice Test Questions
Who can take the RAPS RAC-US Certification Exam?
The targeted audience for the RAPS RAC-US certification exam is regulatory professionals involved in the pharmaceutical and medical device industries. However, candidates from any related field can take the RAPS RAC-US exam provided that they have sufficient knowledge in the area of medical devices and pharmaceuticals regulations. Individuals having designations like Pharmacist, Regulatory Scientist, Medical Device Regulatory Specialist, etc. may also apply. The RAC-US exam dumps say that Senior managers with the ability to make recommendations for a particular company's products and services are also eligible to take the exam. Chat with us now to learn more about the eligibility requirements and other requirements for this certification exam.
NEW QUESTION 39
Company X encounters challenges in the global life cycle management of its medical devices. Which of the following Is MOST appropriate for improving product life cycle management?
- A. Initiate a global submission process after all submission data are finalized.
- B. Identify countries where special requirements exist during the product development phase.
- C. Plan regulatory approval update meetings with senior management and stakeholders.
- D. Utilize the STED template to complete global requirements.
Answer: B
NEW QUESTION 40
According to the ICH guideline on GMP for API, to which of the following is the MOST stringent requirement applied?
- A. Isolation and purification
- B. Physical processing and packaging
- C. Introduction of the API starting material
- D. Production of Intermediate(s)
Answer: B
NEW QUESTION 41
A company is developing a new medical device.
During which initial stage is it MOST appropriate (or a regulatory affairs professional to become involved?
- A. Concept development and validation
- B. Early technical design and product release
- C. Product release and validation
- D. Concept development and early technical design
Answer: D
NEW QUESTION 42
A company is currently marketing an implantable orthopedic medical device. The R&D department is planning to change the material used for the implant. The R&D department states that the change does not impact the safety and effectiveness of the product.
What action should the regulatory affairs professional take FIRST?
- A. Prepare regulatory submissions that detail the medical device's change in materials.
- B. Review the content of change and supporting data for the equivalency with the current material.
- C. No action is needed in this situation.
- D. Write a memo to file since the change does not impact product safety and effectiveness.
Answer: B
NEW QUESTION 43
SOPs for preventive and corrective actions MUST include the procedure to eliminate which of the following?
- A. Late and/or incorrect deliverables
- B. Adverse environmental impacts
- C. Causes of non-conformities
- D. Inadequate training
Answer: C
NEW QUESTION 44
A drug product presents degradation during the manufacturing process. In addition to the amount, what information should be provided FIRST in order to use API overage?
- A. Justification
- B. Specification
- C. Formulation
- D. Property
Answer: A
NEW QUESTION 45
A global company is developing a sophisticated implantable medical device that is coated with antibiotics and biologics to enhance its efficacy.
The product is marketed in Country X.
where it is regulated as a medical device.
The same product, without the antibiotics and biologics, is marketed as a medical device in Country Y.
The company is proposing to start marketing the coated device in Country Y.
Which regulatory approach should the company propose?
- A. Examine decisions made about similar products in Country Y to propose the classification of the product.
- B. Submit the product as a medical device in Country Y as the product is already marketed in Country X as a medical device.
- C. Apply for review of the additional part of the product as a pharmaceutical product in Country
- D. Submit the product for review as a pharmaceutical product in Country Y.
Answer: C
NEW QUESTION 46
Which of the following double-blind clinical trial designs would be MOST appropriate for a
Phase III study with a new product intended to treat an acute life-threatening disease with less than optimal available therapy?
- A. Cross-over
- B. Dose-ranging
- C. Placebo-controlled
- D. Active-controlled
Answer: A
NEW QUESTION 47
In which section of the ICH Common Technical Document will the overview of clinical data appear?
- A. Module 3
- B. Module 2
- C. Module 1
- D. Module 4
Answer: B
NEW QUESTION 48
In order to develop a global drug product, what is the MOST important environmental characteristic to consider in the country of intended use?
- A. Product stability
- B. Product requirements
- C. Product registration
- D. Product formulation
Answer: A
NEW QUESTION 49
A company is developing a new line of products in an area that is new to the company.
What is the BEST approach?
- A. Summarize regulatory documents and history and provide the information to the management team.
- B. Obtain regulatory documents and history and provide the information to R&D.
- C. Obtain competitor research and provide the information to the management team.
- D. Ask the trade association representative to provide an overview of the new product area to the marketing team.
Answer: A
NEW QUESTION 50
At a recent scientific meeting, Company Y had two booths:
* At one booth, Company Y provided brochures on a completed Phase II study.
* In an adjacent booth, Company Y's sales professionals were promoting one of Company
Y's marketed products.
A regulatory affairs-professional at Company X sends a letter to a counterpart at Company
Y requesting that Company Y stop this practice in the future and demanding a formal response to the letter. How should the regulatory affairs professional at Company Y BEST respond?
- A. Acknowledge receipt of the letter in a written response but do nothing further.
- B. Inform the local regulatory authority of the letter and discuss how to respond.
- C. Inform the legal department of the letter and discuss how to respond.
- D. Inform Company X that it has no right to send such a letter and do nothing further.
Answer: C
NEW QUESTION 51
A regulatory authority announces an inspection of a regulatory affairs professional's facility during a holiday season when most of the staff Is not available. What is the MOST practical approach to this dilemma?
- A. Inform the authority that the time is not suitable and request a new time
- B. Insist that key personnel be available for the inspection.
- C. Negotiate with colleagues and the authority to find a better time.
- D. Arrange for an inspection without all intended personnel.
Answer: C
NEW QUESTION 52
During routine surveillance, a regulatory authority sent a company the following communication: "Hepatotoxicity and suicidal behavior were identified as potential safety issues for the company's product. The regulatory authority is evaluating these issues to determine the need for any regulatory action." Which action would be the most appropriate
FIRST step for the company to take?
- A. Contact the regulatory authority to discuss its findings.
- B. Wait for the regulatory authority's final publication on its findings.
- C. Contact the regulatory authority to argue that its conclusions are wrong.
- D. Repeat the Hepatotoxicity tests and send the results to the regulatory authority.
Answer: A
NEW QUESTION 53
According to the GHTF IVD guidance, which of the following is the CORRECT classification for a blood glucose self-testing kit?
- A. Class A
- B. Class B
- C. Class C
- D. Class D
Answer: C
NEW QUESTION 54
The API used for an approved drug product conforms to international monograph specifications and local pharmacopeia; however, the international monograph specifications of the API will be changing soon. Which is the most appropriate action for the regulatory affairs professional to take FIRST?
- A. Analyze the impact of the international monograph change on the local pharmacopeia.
- B. Confirm that the international monograph change is not related to local pharmacopeia.
- C. Transfer the notice of the upcoming international monograph change to QA for further processing.
- D. Prepare the international monograph change submission first and then prepare the local change when required.
Answer: C
NEW QUESTION 55
Company X has a patent for an anti-inflammatory drug that will expire in one year. In order to minimize the effect of the patent expiration, which is the BEST action for the company to take?
- A. Explore litigation strategy for patent infringements on the drug.
- B. Conduct a Phase III study for a new unrelated indication of the drug.
- C. Develop a generic version of the drug.
- D. Develop a better brand-name drug in the same class.
Answer: C
NEW QUESTION 56
A company is developing a new product for the global market. A new international guideline will recommend relevant studies in the pediatric population, and the guideline will be effective before the approval of the company's new product.
What is the BEST advice the regulatory affairs professional can provide to minimize the impact of this guideline on the successful registration of the new product?
- A. The company should initiate the required pediatric studies immediately to avoid costly delays to the current registration plan.
- B. The new guideline has no impact on the current registration plan since all relevant registration studies are almost completed.
- C. The new guideline has no impact on the current registration plan, but the company must be prepared to defend its decision.
- D. The company should consult with relevant regulatory authorities to determine the potential impact on the current registration plan.
Answer: D
NEW QUESTION 57
Which of the following statements regarding the off-label use of drugs is CORRECT?
- A. Sponsors are allowed to distribute publications about unapproved uses of approved drugs and devices as long as the marketing application is under review by the regulatory authority.
- B. The regulatory authority does not restrict physician prescribing for off-label indications or regulate the manufacturer's promotion for such use.
- C. The peer-reviewed literature can ensure high-quality off-label promotion of medications, thereby increasing access to much needed drugs and devices.
- D. Although the regulatory authority reviews and approves drugs for specific indications, the approval does not limit the use of those drugs in clinical practice.
Answer: D
NEW QUESTION 58
A company is preparing the submission package for a drug to be registered in international markets. When preparing the legal documentation, which document MUST comply with the
WHO recommendations?
- A. Certificate of Analysis for the finished product
- B. Certificate of Free Sale
- C. Certificate of Pharmaceutical Product
- D. Certificate of GMP
Answer: C
NEW QUESTION 59
Who has the PRIMARY responsibility for recall of products with quality defects?
- A. Consumer
- B. Regulatory authority
- C. Distributor
- D. Manufacturer
Answer: D
NEW QUESTION 60
In a distribution contract for high-risk medical devices, which of the following regulatory requirements is the MOST important for the distributor?
- A. Written procedure for product traceability
- B. Training program for sales people
- C. Local reimbursement requirements
- D. Service operation procedures
Answer: B
NEW QUESTION 61
Why is it necessary to run supplemental safety pharmacology studies?
- A. To provide adverse reaction reports and the results of the statistical data to the regulatory authority
- B. To comply with regulatory authority requirements related to clinical studies
- C. To substitute the utilization of GLP
- D. To evaluate potential adverse pharmacodynamics effects not addressed by the core battery
Answer: D
NEW QUESTION 62
......
Pass Your RAC-US Exam Easily with Accurate PDF Questions: https://freedumps.validvce.com/RAC-US-exam-collection.html
